Exo Therapeutics Showcases Cutting-Edge Research at ACR
CAMBRIDGE, Mass.--Exo Therapeutics, Inc. is making strides in the realm of drug discovery, specifically with a focus on innovative treatments for autoimmune diseases. This pre-clinical company specializes in developing a range of drug candidates that target exosites—unique binding pockets distant from traditional sites—leading to significant advancements in therapeutic precision.
Exciting Presentation Details
During the upcoming American College of Rheumatology’s Convergence, happening from November 14 to November 19, 2024, in Washington, D.C., Exo Therapeutics will present a highly anticipated late-breaking poster. This presentation is set to highlight the company's revolutionary findings and research methodologies.
Poster Highlights
The poster will feature an important abstract titled: Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NF?B Responses for Treatment of Autoimmune Diseases. The session will take place on November 18 and will be presented by Bhavatarini Vangamudi, Ph.D.
Presentation Logistics
This engaging presentation will occur between 10:30 AM and 12:30 PM. It is part of the Late-Breaking Posters session, attracting attention from industry leaders and researchers eager to learn about novel therapeutic strategies. The poster is categorized under Abstract ID: 1943848, with final number L01.
About Exo Therapeutics
Co-founded by prominent scientists including Professors David R. Liu, Alan Saghatelian, and Juan Pablo Maianti, Exo Therapeutics focuses on addressing tough pharmaceutical targets through innovative methods. Their ExoSightTM platform enables the discovery and development of potent small molecule drugs targeting exosites. By opening up new avenues in enzyme activity modulation, Exo Therapeutics aims to create robust therapeutic effects across various disease areas, including inflammation and oncology.
The Impact on Therapy Development
At Exo Therapeutics, a team of distinguished researchers is dedicated to unlocking breakthrough therapeutics. The unique approach to targeting exosites could lead to therapies that offer precise interventions in autoimmune diseases, thereby enhancing treatment efficacy and patient outcomes.
Frequently Asked Questions
What is the significance of the presentation at ACR?
The presentation provides a platform for Exo Therapeutics to share groundbreaking research on innovative treatments for autoimmune diseases.
Who is presenting the poster?
Bhavatarini Vangamudi, Ph.D., will be the presenting author of the poster at the ACR event.
When and where will the poster be presented?
The poster will be presented on November 18 during the Late-Breaking Posters session at the American College of Rheumatology's Convergence event in Washington, D.C.
What is the focus of the poster's research?
The focus is on targeted exosite inhibition, particularly in mitigating unwanted immune responses in autoimmune diseases.
How does Exo Therapeutics approach drug discovery?
Exo Therapeutics employs unique methodologies leveraging exosite targeting to enhance drug efficacy and specificity, aiming to address complex diseases.
